Ugurel S - Search Results

1

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R. Hoek KS, et al. Among authors: ugurel s. Pigment Cell Res. 2006 Aug;19(4):290-302. doi: 10.1111/j.1600-0749.2006.00322.x. Pigment Cell Res. 2006. PMID: 16827748

2

Systemic treatment in advanced melanoma: innovative perspectives.

Ugurel S, Schadendorf D. Ugurel S, et al. Onkologie. 2003 Jun;26(3):234-8. doi: 10.1159/000071618. Onkologie. 2003. PMID: 12845207 Review.

3

Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?

Ugurel S, Lindemann M, Schadendorf D, Grosse-Wilde H. Ugurel S, et al. Cancer Immunol Immunother. 2004 Nov;53(11):1051. doi: 10.1007/s00262-004-0565-1. Epub 2004 Jun 30. Cancer Immunol Immunother. 2004. PMID: 15232653 Free PMC article. No abstract available.

4

Immunogenicity of constitutively active V599EBRaf.

Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Bröcker EB, Straten Pt, Rapp UR, Becker JC. Andersen MH, et al. Among authors: ugurel s. Cancer Res. 2004 Aug 1;64(15):5456-60. doi: 10.1158/0008-5472.CAN-04-0937. Cancer Res. 2004. PMID: 15289355

5

Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.

Bloethner S, Chen B, Hemminki K, Müller-Berghaus J, Ugurel S, Schadendorf D, Kumar R. Bloethner S, et al. Among authors: ugurel s. Carcinogenesis. 2005 Jul;26(7):1224-32. doi: 10.1093/carcin/bgi066. Epub 2005 Mar 10. Carcinogenesis. 2005. PMID: 15760917

6

Lack of clinical efficacy of imatinib in metastatic melanoma.

Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, Schadendorf D. Ugurel S, et al. Br J Cancer. 2005 Apr 25;92(8):1398-405. doi: 10.1038/sj.bjc.6602529. Br J Cancer. 2005. PMID: 15846297 Free PMC article. Clinical Trial.

7

Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.

Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Ugurel S, et al. Int J Cancer. 2005 Dec 10;117(5):825-30. doi: 10.1002/ijc.21073. Int J Cancer. 2005. PMID: 15957165

8

Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.

Bloethner S, Hemminki K, Thirumaran RK, Chen B, Mueller-Berghaus J, Ugurel S, Schadendorf D, Kumar R. Bloethner S, et al. Among authors: ugurel s. Melanoma Res. 2006 Aug;16(4):297-307. doi: 10.1097/01.cmr.0000222597.50309.05. Melanoma Res. 2006. PMID: 16845325

9

Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma.

Thoelke A, Schmid HP, Figl R, Schadendorf D, Ugurel S. Thoelke A, et al. Among authors: ugurel s. Eur J Dermatol. 2006 Jul-Aug;16(4):428-30. Eur J Dermatol. 2006. PMID: 16935804

10

Re: Association between endothelin receptor B nonsynonymous variants and melanoma risk.

Thirumaran RK, Thoelke A, Ugurel S, Hemminki K, Schadendorf D, Kumar R. Thirumaran RK, et al. Among authors: ugurel s. J Natl Cancer Inst. 2006 Sep 6;98(17):1252-3; author reply 1253. doi: 10.1093/jnci/djj336. J Natl Cancer Inst. 2006. PMID: 16954478 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

314 results

Search Page

Filters